Press release from Companies
Published: 2025-04-29 16:04:18
Bio-Works Technologies AB (publ) has received an order worth approximately SEK 2.4 million from a new European customer active in veterinary vaccine production. The product will be used in manufacturing processes with recurring delivery needs.
"We see it as a strong endorsement that a new player in vaccine production chooses Bio-Works as a supplier. This strengthens our position in the European market," says Lone Carlbom, CEO of Bio-Works Technologies AB.
The delivery concerns products used in the production process and represents a potential for long-term collaboration.
This disclosure contains information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 29-04-2025 16:04 CET.
Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Lone Carlbom, CEO, e-mail: lone.carlbom@bio-works.com, phone: +46(0)8-502 705 84.
About Bio-Works
Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.
Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For more information, visit www.bio-works.com.
